ALDX — Aldeyra Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1341235 ·
Last close
$0.69
Market Cap
$41.88M
52W High
$5.93
52W Low
$0.53
ADV30
953,351
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -4,136,274 -3,762,964 43,381,909 40,974,979 8,159,697
Jun 2026 0 — -5,850,507 -5,450,273 47,540,559 45,089,786 9,655,256
Mar 2026 0 — -3,546,918 -3,452,619 66,483,081 65,002,305 24,326,289
Dec 2025 0 — -6,667,883 -6,461,507 72,059,317 70,041,254 27,808,927

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-22,020,272
Investing CF
$40,976,903
Financing CF
$-15,108,114
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.44
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-492,860,145
Inventory
—
Receivables
$755,545
ST Investments
$0
EBIT TTM
$-21,632,877
Pretax Income TTM
$-23,052,740
Interest Exp TTM
$1,419,863
Analysts
5

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -35,265,206 -33,846,661 72,059,317 27,808,927 44,250,390 -33,345,682
Dec 2024 0 -60,117,032 -55,851,444 104,606,694 33,601,823 71,004,871 -43,208,747
Dec 2023 0 -42,794,083 -37,542,510 148,326,911 28,531,881 119,795,030 -30,326,128
Dec 2022 0 -62,679,987 -62,024,636 181,291,657 30,283,628 151,008,029 -56,637,187
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$2,433,564
NetIncome TTM
$-23,052,740
OpCashFlow TTM
—
Assets (Latest)
$47,540,559
Forward EPS
$-0.28

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $0.50 · spot: $0.67 · call volume: 11 · put volume: 1

Peers — same industry

TickerNameMarket CapLastDaily %
TLPH TALPHERA, INC. $41.61M $0.80 —
ATNM Actinium Pharmaceuticals, Inc. $42.45M $1.35 —
DWTX Dogwood Therapeutics, Inc. $41.29M $1.08 —
HYFT MindWalk Holdings Corp. $42.60M $0.91 —
PLRX PLIANT THERAPEUTICS, INC. $40.93M $0.66 —

News headlines (Yahoo Finance, 1h cache)

Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
2026-09-29 15:02 · Yahoo
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter
2026-09-29 14:49 · Yahoo
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
2026-09-29 11:00 · Yahoo
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
2026-10-15 13:33 · Yahoo
Here's Why You Should Add ANRO Stock to Your Portfolio Now
2026-10-14 12:59 · Yahoo
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
2026-10-14 12:52 · Yahoo
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
2026-10-12 15:24 · Yahoo
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
2026-10-12 14:55 · Yahoo
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
2026-10-09 16:55 · Yahoo
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
2026-10-09 14:53 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.